Promus ELITE™

Everolimus-Eluting Platinum Chromium Coronary Stent System

Trusted Stent Platform

The customized architecture design of the Promus ELITE Stent provides the ideal balance of strength and flexibility for excellent acute performance and patient outcomes.

Promus ELITE Strut Detail

Bench testing has shown:

Improved Conformability
Up to 8X more conformable1
Unmatched Radial Strength
Up to 24% higher radial strength1
Reduced Recoil
50% less recoil than competitive DES1
Best-in-Class Visibility
Unique PtCr stent platform
Superior Conformability
Up to 8X more conformable1
Unmatched Radial Strength
Up to 24% higher radial strength1
Reduced Recoil
50% less recoil than competitive DES1
Best-in-Class Visibility
Unique PtCr stent platform
 

Low Recoil. Unmatched Radial Strength.

The Promus ELITE Stent System offers exceptional strength and 50% less recoil than competitive drug-eluting stents.

Radial Strength Test1

Chart showing the Promus ELITE Stent has demonstrated up to 24% more radial strength than competitive drug-eluting stents.

Recoil Test1

Chart showing the Promus ELITE Stent System has demonstrated 50% less recoil then competitive drug-eluting stents.

Less Vessel Straightening

Promus PtCr EES offers exceptional conformability that maintains the natural vessel curvature and demonstrated significantly less change in vessel angulation in the PLATINUM Workhorse Trial.2
Chart showing Promus PtCr EES demonstrated significantly less change in vessel angulation.

Best-in-Class Visibility3

Highly visibile PtCr alloy.

Drug Distribution and Uniformity

The Promus ELITE Stent System leverages the market-leading Everolimus drug and PVDF-HFP polymer, which provide excellent drug distribution and uniformity.
Product Overview

Product Overview

Built to offer outstanding acute performance and proven long-term outcomes.

Button
Deliverability

Deliverability

Enhanced delivery system for the optimal balance of pushability, flexibility and trackability.

Button
Clinical Outcomes

Clinical Outcomes

Proven outcomes in 11 studies of almost 10,000 patients in the PLATINUM Family of trials.

Button
Top